Dr Blagoje Soskic | Postdoctoral Fellow

Soskic, Blagoje

Blagoje is a Postdoc at Gosia Trynka’s group. He uses high-throughput technologies to investigate the impact of genetic variation on T cell function.

Throughout my education I have been fascinated by the complexity of the mechanisms that control our immune system. This led me to undertake my PhD training with Prof. David Sansom at UCL, where I gained a valuable understanding of the cell biology behind the control of T cell activation. During those years I realised that the processes that control immune reactions are highly variable and that understanding their genetic control could generate tremendous insight into the development of diseases. Motivated by this, I decided to research the genetic control of T cell activation. During my postdoctoral training in Dr Gosia Trynka’s group, I bridged functional immunology with genomic tools in order to take the next steps in understanding how genetic variants lead to complex immune diseases and how to identify new drug targets. I focused on generating large scale data on different immune cell types and states and developing statistical methods that enable the translation of genetic variants into immune functions.

Publications

  • Chromatin activity at GWAS loci identifies T cell states driving complex immune diseases.

    Soskic B, Cano-Gamez E, Smyth DJ, Rowan WC, Nakic N et al.

    Nature genetics 2019;51;10;1486-1493

  • Immunogenomic approaches to understand the function of immune disease variants.

    Glinos DA, Soskic B and Trynka G

    Immunology 2017;152;4;527-535

  • Genetic variation at the CD28 locus and its impact on expansion of pro-inflammatory CD28 negative T cells in healthy individuals.

    Liaskou E, Jeffery L, Chanouzas D, Soskic B, Seldin MF et al.

    Scientific reports 2017;7;1;7652

  • Identifying functional defects in patients with immune dysregulation due to LRBA and CTLA-4 mutations.

    Hou TZ, Verma N, Wanders J, Kennedy A, Soskic B et al.

    Blood 2017;129;11;1458-1468

  • A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding.

    Douthwaite J, Moisan J, Privezentzev C, Soskic B, Sabbah S et al.

    Journal of immunology (Baltimore, Md. : 1950) 2017;198;1;528-537

Soskic, Blagoje